Massachusetts governor warns healthcare execs to be realistic about AI

Massachusetts Gov. Charlie Baker issued a piece of cautionary advice to healthcare executives April 8, urging them to take the recent rise of AI with a grain of salt, the Boston Business Journal reported.

Baker, a former health insurance executive and health and human services chief under Gov. William Weld, warned attendees of the Partners HealthCare World Medical Innovation Forum in Boston that while AI can certainly contribute to better health outcomes, researchers need to be careful in the way they roll out the tech.

“My advice is to recognize and understand the people in healthcare get held to a higher standard,” he said. “That’s just the way it is. And that’s not a bad thing, because people believe in you and what you’re capable of and what you can do.”

The process of developing reputable, reliable AI could suffer under that microscope. Baker, who’s familiar with the investment side of AI, said innovators are eager to get their solutions to market but are often unable to deliver solid results in the timeframe they predicted.

Baker said he’s a “big believer in the deployment of technology,” but warned researchers to be realistic about both the capabilities of their innovations and their potential shortcomings.

“I just hope I’m alive long enough to benefit from your ability to deploy all this stuff, to deliver higher outcomes, better results for really complicated people who are dealing with really difficult things,” he said.

Read the full story below:

""

After graduating from Indiana University-Bloomington with a bachelor’s in journalism, Anicka joined TriMed’s Chicago team in 2017 covering cardiology. Close to her heart is long-form journalism, Pilot G-2 pens, dark chocolate and her dog Harper Lee.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup